SHP2 drugs for Non-Small Cell Lung Cancer

3 tracked SHP2 drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the SHP2 page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.

1 Phase 31 Phase 1/21 Phase 1

Head-to-head evidence: GH21 vs HBI-2376 · GH21 vs Sitneprotafib · HBI-2376 vs Sitneprotafib

The roster

← all SHP2 drugs